Modality
Fusion Protein
MOA
STINGag
Target
JAK2
Pathway
Cell Cycle
Pancreatic Ca
Development Pipeline
Preclinical
Dec 2019
→ Jan 2025
PreclinicalCurrent
NCT04302676
1,721 pts·Pancreatic Ca
2020-12→TBD·Not yet recruiting
NCT05768565
682 pts·Pancreatic Ca
2019-12→2025-01·Active
2,403 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-271.2y agoInterim· Pancreatic Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
Preclinical
Active
Preclinical
Not yet…
Catalysts
Interim
2025-01-27 · 1.2y ago
Pancreatic Ca
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04302676 | Preclinical | Pancreatic Ca | Not yet recr... | 1721 | DOR |
| NCT05768565 | Preclinical | Pancreatic Ca | Active | 682 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| Tezelucimab | Ascendis Pharma | Preclinical | SHP2 |